Author Correction: Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Correction Notice: Mutations in CSF1R and Other Receptor Tyrosine Kinases Associated with Histiocytic Neoplasms

  • By

  • Benjamin H. Durham

  • Estibaliz Lopez Rodrigo

  • Jennifer Picarsic

  • David Abramson

  • Veronica Rotemberg

  • Steven De Munck

  • Erwin Pannecoucke

  • Sydney X. Lu

  • Alessandro Pastore

  • Akihide Yoshimi

  • Diana Mandelker

  • Ozge Ceyhan-Birsoy

  • Gary A. Ulaner

  • Michael Walsh

  • Mariko Yabe

  • Kseniya Petrova-Drus

  • Maria E. Arcila

  • Marc Ladanyi

  • David B. Solit

  • Michael F. Berger

  • David M. Hyman

  • Mario E. Lacouture

  • Caroline Erickson

  • Ruth Saganty

  • Michelle Ki

  • Ira J. Dunkel

  • Vicente Santa-María López

  • Jaume Mora

  • Julien Haroche

  • Jean-Francois Emile

  • Olivier Decaux

  • Frederic Geissmann

  • Savvas N. Savvides

  • Alexander Drilon

  • Eli L. Diamond

  • Omar Abdel-Wahab

  • September 1, 2026

Share

Clinical Report: Correction Notice on CSF1R Mutations in Histiocytic Neoplasms

Overview

This correction notice addresses an error in the original publication regarding the actin lane in Extended Data Fig. 10f of a Nature Medicine article (doi:10.1038/s41591-019-0653-6). The corrected figure now accurately reflects the full-length, uncropped blot.

Background

Mutations in CSF1R and other receptor tyrosine kinases (RTKs) are significant in the context of histiocytic neoplasms, which are increasingly recognized as clonal myeloid disorders. Understanding these mutations is crucial for accurate diagnosis and treatment, as they are linked to downstream signaling pathways that drive disease progression.

Data Highlights

No numerical or trial data is presented in the correction notice, which focuses solely on the correction of the figure.

Key Findings

  • The correction addresses an error in the actin lane of Extended Data Fig. 10f.
  • The corrected figure is now consistent with the corresponding full-length, uncropped blot.
  • Activating mutations in CSF1R are associated with histiocytic neoplasms.
  • RTK alterations are linked to MAPK pathway activation in histiocytoses.
  • New consensus recommendations emphasize the importance of molecular profiling in diagnosing malignant histiocytic neoplasms.

Clinical Implications

Accurate representation of data in published research is essential for clinicians relying on these findings for patient management.

Conclusion

This correction serves to clarify previously published findings regarding CSF1R mutations in histiocytic neoplasms.

Related Resources & Content

  1. Nature Medicine, 2019 -- Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms
  2. Blood Cancer Journal — Chronic Myelomonocytic Leukemia (CMML) with CSF3R T618I Mutation Represents a Proliferative Subtype Associated with ASXL1 Mutations and Poor Prognosis
  3. Blood Cancer Journal — Co-occurrence of CSF3R T618I Mutation with Splicing and Epigenetic Gene Alterations and a Novel PIM3 Truncated Fusion in Chronic Neutrophilic Leukemia
  4. Frontiers in Oncology — Correction: Multiple myeloma in the real world settings: prognostic significance of 1q21 chromosomal abnormalities - single center experience
  5. jadpro — Chronic Neutrophilic Leukemia: A Case Report of a Rare Myeloproliferative Neoplasm With a CSF3R Mutation
  6. Activating mutations in CSF-1R and additional receptor tyrosine kinases in histiocytic neoplasms - PMC
  7. Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology - PubMed
  8. Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms | Nature Medicine

Original Source(s)

Author Correction: Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms

  • by Benjamin H. Durham, Estibaliz Lopez Rodrigo, Jennifer Picarsic, David Abramson, Veronica Rotemberg, Steven De Munck, Erwin Pannecoucke, Sydney X. Lu, Alessandro Pastore, Akihide Yoshimi, Diana Mandelker, Ozge Ceyhan-Birsoy, Gary A. Ulaner, Michael Walsh, Mariko Yabe, Kseniya Petrova-Drus, Maria E. Arcila, Marc Ladanyi, David B. Solit, Michael F. Berger, David M. Hyman, Mario E. Lacouture, Caroline Erickson, Ruth Saganty, Michelle Ki, Ira J. Dunkel, Vicente Santa-María López, Jaume Mora, Julien Haroche, Jean-Francois Emile, Olivier Decaux, Frederic Geissmann, Savvas N. Savvides, Alexander Drilon, Eli L. Diamond, Omar Abdel-Wahab

  • September 1, 2026

Related Content

New Podcast Feature: Dr. Geoffrey Young on SurgOnc Today

Join Baptist Health's Dr. Geoffrey Young as he joins Drs. Sonia Cohen and Ashley Holder on the latest episode of SurgOnc Today.

  • by

  • August 28, 2026

  • 1 min
Genetic Testing in Retinoblastoma: New Applications

Liquid biopsy and molecular profiling are expanding the diagnostic and prognostic role of genetic testing in retinoblastoma.

Correction: Primary cutaneous adenoid cystic carcinoma of the right forearm: a case report and dermoscopic features